Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|July 22, 2016
Quay Pharma Completes FDA Pre-Qualification Inspection
Author(s)Pharmaceutical Technology Editors
The company announced that its facilities and laboratories have completed FDA pre-qualification inspection.
Advertisement
On July 19, 2016, Quay Pharma announced that its laboratories and manufacturing facilities have completed FDA pre-qualification inspection. The inspection confirmed that the company’s systems are GMP compliant and no deficiencies were identified. Quay recently invested £3 million (approximately $3.93 million) in GMP manufacturing suites. The company also recently received a Commercial License from the Medicines and Healthcare Products Regulatory Agency.
Source: Quay Pharma
Advertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
Pharma Leaders Weigh in On AI's Measurable Results In 2026
3
AAPS PharmSci 360 2026: E&L Standards Harmonization
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5